Skip to Content

Generic Requip XL Availability

See also: Generic Requip

Requip XL is a brand name of ropinirole, approved by the FDA in the following formulation(s):

REQUIP XL (ropinirole hydrochloride - tablet, extended release;oral)

Has a generic version of Requip XL been approved?

A generic version of Requip XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Requip XL and have been approved by the FDA:

ropinirole hydrochloride tablet, extended release;oral

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: May 17, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: ALEMBIC LTD
    Approval date: April 22, 2013
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: June 6, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: October 15, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: SANDOZ INC
    Approval date: June 6, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: WATSON LABS INC
    Approval date: June 6, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]
  • Manufacturer: WOCKHARDT LTD
    Approval date: August 27, 2012
    Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB], EQ 8MG BASE [AB], EQ 12MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Requip XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Hydrophilic/lipophilic polymeric matrix dosage formulation
    Patent 7,927,624
    Issued: April 19, 2011
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Maggi; Lauretta & Conte; Ubaldo
    Assignee(s): Jagotec AG
    An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
    Patent expiration dates:
    • December 2, 2021
      ✓ 
      Patent use: A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
      ✓ 
      Drug product
  • Hydrophilic/lipophilic polymeric matrix dosage formulation
    Patent 8,303,986
    Issued: November 6, 2012
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Maggi; Lauretta & Conte; Ubaldo
    Assignee(s): Jagotec AG
    An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
    Patent expiration dates:
    • April 12, 2021
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide